Positive News Sentiment NASDAQ:ADVM Adverum Biotechnologies Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Adverum Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.23 +0.07 (+6.03%) (As of 07/6/2022 12:00 AM ET) Add Compare Share Today's Range$1.17▼$1.2350-Day Range$0.81▼$1.2352-Week Range$0.80▼$3.66Volume892,024 shsAverage Volume1.39 million shsMarket Capitalization$121.49 millionP/E RatioN/ADividend YieldN/APrice Target$3.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Adverum Biotechnologies MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside184.6% Upside$3.50 Price TargetShort InterestBearish6.08% of Float Sold ShortDividend StrengthN/ASustainability-0.78Upright™ Environmental ScoreNews SentimentN/AInsider TradingAcquiring Shares$111,944 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.57) to ($1.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.63 out of 5 starsMedical Sector57th out of 1,433 stocksBiological Products, Except Diagnostic Industry8th out of 220 stocks 3.0 Analyst's Opinion Consensus RatingAdverum Biotechnologies has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.50, Adverum Biotechnologies has a forecasted upside of 184.6% from its current price of $1.23.Amount of Analyst CoverageAdverum Biotechnologies has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.08% of the float of Adverum Biotechnologies has been sold short.Short Interest Ratio / Days to CoverAdverum Biotechnologies has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Adverum Biotechnologies has recently decreased by 4.05%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAdverum Biotechnologies does not currently pay a dividend.Dividend GrowthAdverum Biotechnologies does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAdverum Biotechnologies has received a 77.25% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physiological diseases ", "Preclinical research services for mental health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Adverum Biotechnologies is -0.78. Previous Next 3.3 News and Social Media Coverage News SentimentAdverum Biotechnologies has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Adverum Biotechnologies this week, compared to 1 article on an average week.Search Interest3 people have searched for ADVM on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Adverum Biotechnologies to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adverum Biotechnologies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $111,944.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders12.40% of the stock of Adverum Biotechnologies is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.82% of the stock of Adverum Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Adverum Biotechnologies are expected to grow in the coming year, from ($1.57) to ($1.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adverum Biotechnologies is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adverum Biotechnologies is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdverum Biotechnologies has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ADVM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adverum Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address About Adverum Biotechnologies (NASDAQ:ADVM) StockAdverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.Read More ADVM Stock News HeadlinesJuly 6, 2022 | finance.yahoo.comAdverum Biotechnologies Completes IND Amendment and Prepares to Initiate the Phase 2 LUNA Trial of ADVM-022 in Wet AMDJune 24, 2022 | finance.yahoo.comAdverum Biotechnologies Granted Priority Medicines (PRIME) Designation by European Medicines Agency for ADVM-022 in Wet AMDJuly 7, 2022 | Investing Daily (Ad)27 U.S. Cities Where Stocks Yield 26% a YearWhat’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. June 17, 2022 | americanbankingnews.comBrokerages Set Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Price Target at $4.50June 9, 2022 | finance.yahoo.comAdverum Biotechnologies Presents Three-Year Aflibercept Protein Expression and Improvement in Anatomic Outcomes After a Single IVT Injection of ADVM-022 in the OPTIC Study in Wet AMDJune 2, 2022 | finance.yahoo.comAdverum Biotechnologies Announces New Data at the Macula Society’s 2022 Annual MeetingMay 19, 2022 | finance.yahoo.comAdverum Biotechnologies Presents Research Pipeline Data Supporting Utility of its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene TherapyMay 17, 2022 | finance.yahoo.comAdverum Presents Data at ASGCT Further Supporting Phase 2 Development Plans for ADVM-022July 7, 2022 | Weekly Investor Alerts (Ad)A Bigger Opportunity For Growth…A smaller stock with a relatively low market cap often outperforms a larger company stock with a much higher market cap… And when an investor is spending fewer dollars for a stock purchase there’s a bigger opportunity for growth. Click Here for Our Top 5 Microcap Stocks. May 13, 2022 | seekingalpha.comAdverum Biotechnologies GAAP EPS of -$0.38 misses by $0.07May 11, 2022 | finance.yahoo.comHow Much Of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Do Institutions Own?May 4, 2022 | morningstar.comAdverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2022 | MorningstarMay 2, 2022 | finance.yahoo.comAdverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2022May 2, 2022 | finance.yahoo.comAdverum Bio Posts Additional Efficacy, Safety Data From ADVM-022 Gene Therapy In Wet AMDApril 21, 2022 | nasdaq.comThursday 4/21 Insider Buying Report: TPL, ADVMApril 7, 2022 | finance.yahoo.comAdverum Moves Forward With IND Amendment For ADVM-022 Phase 2 Trial In Wet AMDApril 6, 2022 | seekingalpha.comAdverum gets FDA feedback on mid-stage trial for Wet AMD candidateApril 6, 2022 | finance.yahoo.comAdverum Biotechnologies Proceeds with IND Amendment for ADVM-022 Phase 2 Trial in Wet AMD After Receiving Requested Type C Meeting Feedback from the FDAMarch 29, 2022 | seekingalpha.comAdverum Biotechnologies GAAP EPS of -$0.35 misses by $0.01March 29, 2022 | finance.yahoo.comAdverum Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial ResultsMarch 2, 2022 | nasdaq.comShould You Buy Adverum Biotechnologies (ADVM) Ahead of Earnings?February 28, 2022 | finance.yahoo.comAdverum Biotechnologies to Participate in the 42nd Annual Cowen Healthcare ConferenceFebruary 15, 2022 | finance.yahoo.comInsiders who bought in the last 12 months lose an additional US$367k as Adverum Biotechnologies, Inc. (NASDAQ:ADVM) drops to US$136mFebruary 7, 2022 | seekingalpha.comAdverum Biotechnologies names new CMOFebruary 7, 2022 | finance.yahoo.comAdverum Biotechnologies Appoints Richard Beckman M.D. as Chief Medical OfficerJanuary 6, 2022 | finance.yahoo.comAdverum Biotechnologies Appoints Star Seyedkazemi, Pharm.D. as Chief Development OfficerJanuary 4, 2022 | finance.yahoo.comAdverum Biotechnologies Granted Orphan Drug Designation by FDA for Gene Therapy Candidate in Preclinical Development for the Treatment of Blue Cone MonochromacySee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADVM CUSIPN/A CIK1501756 Webwww.adverum.com Phone(650) 656-9323Fax650-329-8151Employees188Year FoundedN/ACompany Calendar Last Earnings5/12/2022Today7/07/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$3.50 High Stock Price Forecast$6.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+184.6%Consensus RatingHold Rating Score (0-4)2 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-145,540,000.00 Net MarginsN/A Pretax Margin-1,940.53% Return on Equity-46.82% Return on Assets-33.27% Debt Debt-to-Equity RatioN/A Current Ratio12.06 Quick Ratio12.05 Sales & Book Value Annual Sales$7.50 million Price / Sales16.20 Cash FlowN/A Price / Cash FlowN/A Book Value$3.22 per share Price / Book0.38Miscellaneous Outstanding Shares98,770,000Free Float94,622,000Market Cap$121.49 million OptionableOptionable Beta1.02 Adverum Biotechnologies Frequently Asked Questions Should I buy or sell Adverum Biotechnologies stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Adverum Biotechnologies stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADVM, but not buy additional shares or sell existing shares. View analyst ratings for Adverum Biotechnologies or view top-rated stocks. What is Adverum Biotechnologies' stock price forecast for 2022? 5 analysts have issued 12-month price objectives for Adverum Biotechnologies' shares. Their ADVM stock forecasts range from $2.00 to $6.00. On average, they predict Adverum Biotechnologies' share price to reach $3.50 in the next twelve months. This suggests a possible upside of 184.6% from the stock's current price. View analysts' price targets for Adverum Biotechnologies or view top-rated stocks among Wall Street analysts. How has Adverum Biotechnologies' stock price performed in 2022? Adverum Biotechnologies' stock was trading at $1.76 at the beginning of 2022. Since then, ADVM stock has decreased by 30.1% and is now trading at $1.23. View the best growth stocks for 2022 here. When is Adverum Biotechnologies' next earnings date? Adverum Biotechnologies is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Adverum Biotechnologies. How were Adverum Biotechnologies' earnings last quarter? Adverum Biotechnologies, Inc. (NASDAQ:ADVM) announced its quarterly earnings data on Thursday, May, 12th. The biotechnology company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.34) by $0.04. View Adverum Biotechnologies' earnings history. Who are Adverum Biotechnologies' key executives? Adverum Biotechnologies' management team includes the following people: Dr. Laurent Fischer, Pres, CEO & Director (Age 58, Pay $921.08k) (LinkedIn Profile)Mr. Kishor Peter Soparkar J.D., Chief Operating Officer (Age 51, Pay $622.55k)Dr. Brigit Riley Ph.D., Chief Scientific Officer (Age 44, Pay $816.08k)Mr. John W. Rakow J.D., Sr. VP, Gen. Counsel & Acting CFO (Age 65)Ms. Nancy E. Pecota, Principal Accounting Officer (Age 62)Mr. Heikki Jouttijarvi, Sr. VP & Head of Technical OperationsMs. Dena House, Sr. VP of HR, Organizational Devel. & LearningMs. Carla Fiankan, Sr. VP of Regulatory AffairsDr. Jim Wang Ph.D., Chief Regulatory OfficerMr. Thomas Kochy, Sr. VP and Head of Global Product Strategy & Commercial What is Laurent Fischer, M.D.'s approval rating as Adverum Biotechnologies' CEO? 3 employees have rated Adverum Biotechnologies CEO Laurent Fischer, M.D. on Glassdoor.com. Laurent Fischer, M.D. has an approval rating of 72% among Adverum Biotechnologies' employees. Who are some of Adverum Biotechnologies' key competitors? Some companies that are related to Adverum Biotechnologies include C4 Therapeutics (CCCC), Aura Biosciences (AURA), ADMA Biologics (ADMA), Kodiak Sciences (KOD), Aerie Pharmaceuticals (AERI), HilleVax (HLVX), Mesoblast (MESO), Adagio Therapeutics (ADGI), Humacyte (HUMA), MeiraGTx (MGTX), bluebird bio (BLUE), Forma Therapeutics (FMTX), Caribou Biosciences (CRBU), Tarsus Pharmaceuticals (TARS) and DBV Technologies (DBVT). View all of ADVM's competitors. What other stocks do shareholders of Adverum Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adverum Biotechnologies investors own include CTI BioPharma (CTIC), California Resources (CRC), CA (CA), BlackRock (BLK), Amarin (AMRN), Endologix (ELGX), Immunomedics (IMMU), Advanced Micro Devices (AMD), Aurinia Pharmaceuticals (AUPH) and Genocea Biosciences (GNCA). What is Adverum Biotechnologies' stock symbol? Adverum Biotechnologies trades on the NASDAQ under the ticker symbol "ADVM." How do I buy shares of Adverum Biotechnologies? Shares of ADVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Adverum Biotechnologies' stock price today? One share of ADVM stock can currently be purchased for approximately $1.23. How much money does Adverum Biotechnologies make? Adverum Biotechnologies (NASDAQ:ADVM) has a market capitalization of $121.49 million and generates $7.50 million in revenue each year. The biotechnology company earns $-145,540,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis. How many employees does Adverum Biotechnologies have? Adverum Biotechnologies employs 188 workers across the globe. How can I contact Adverum Biotechnologies? Adverum Biotechnologies' mailing address is 800 Saginaw Drive, Redwood City CA, 94063. The official website for Adverum Biotechnologies is www.adverum.com. The biotechnology company can be reached via phone at (650) 656-9323, via email at mlacy@adverum.com, or via fax at 650-329-8151. This page (NASDAQ:ADVM) was last updated on 7/7/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
